Log in | Register

Conflicts of interest in infection prevention and control research: no smoke without fire. A narrative review

Mohamed Abbas| Daniela Pires| Alexandra Peters| Chantal M Morel| Samia Hurst| Alison Holmes| Hiroki Saito| Benedetta Allegranzi| Jean-Christophe Lucet| Walter Zingg| Stephan Harbarth| Didier Pittet
Review
Volume 44, Issue 10 / October , 2018

Pages 1679 - 1690

Abstract

Conflicts of interest (COIs) do occur in healthcare research, yet their impact on research in the field of infection prevention and control (IPC) is unknown. We conducted a narrative review aiming to identify examples of COIs in IPC research. In addition to well-known instances, we conducted PubMed and Google searches to identify and report case studies of COIs in IPC and antimicrobial resistance (AMR), which were chosen arbitrarily following consensus meetings, to illustrate different types of COIs. We also searched the Retraction Watch database and blog to systematically identify retracted IPC and/or infectious disease-related papers. Our review highlights COIs in academic research linked to ties between industry and physicians, journal editors, peer-reviewed journals' choice for publication, and guideline committees participants and authors. It explores how COIs can affect research and could be managed. We also present several selected case studies that involve (1) the chlorhexidine industry and how it has used marketing trials and key opinion leaders to promote off-label use of its products; (2) the copper industry and how reporting of its trials in IPC have furthered their agenda; (3) the influence of a company developing “closed infusion systems” for catheters and how this affects networks in low- and middle-income countries and guideline development; (4) potential perverse incentives hospitals may have in reporting healthcare-associated infection or AMR rates and how government intervention may restrict AMR research for fear of bad publicity and subsequent negative economic consequences. Finally, the analysis of reasons for the retraction of previously published papers highlights the fact that misconduct in research may have other motivations than financial gain, the most visible form of COIs. COIs occur in the field of research in general, and IPC and AMR are no exceptions. Their effects pervade all aspects of the research and publication processes. We believe that, in addition to improvements in management strategies of COIs, increased public funding should be available to decrease researchers’ dependency on industry ties. Further research is needed on COIs and their management.

Keywords

References

  1. Thompson DF (1993) Understanding financial conflicts of interest. N Engl J Med 329(8):573–576
    • View reference on publisher's website
    • View reference on PubMed
  2. Goodman S, Dickersin K (2011) Metabias: a challenge for comparative effectiveness research. Ann Intern Med 155(1):61–62
    • View reference on publisher's website
    • View reference on PubMed
  3. Wiersma M, Kerridge I, Lipworth W (2018) Dangers of neglecting non-financial conflicts of interest in health and medicine. J Med Ethics 44(5):319–322
    • View reference on publisher's website
    • View reference on PubMed
  4. Luty J, Arokiadass SM, Easow JM, Anapreddy JR (2009) Preferential publication of editorial board members in medical specialty journals. J Med Ethics 35(3):200–202
    • View reference on publisher's website
    • View reference on PubMed
  5. Abdoul H, Perrey C, Tubach F, Amiel P, Durand-Zaleski I, Alberti C (2012) Non-financial conflicts of interest in academic grant evaluation: a qualitative study of multiple stakeholders in France. PLoS One 7(4):e35247
    • View reference on publisher's website
    • View reference on PubMed
  6. Partnerships for Children and Health (2017) In: Andonova LB (ed) Governance entrepreneurs: international organizations and the rise of global public-private partnerships. Business and public policy. Cambridge University Press, Cambridge, pp 145–192
  7. Tringale KR, Marshall D, Mackey TK, Connor M, Murphy JD, Hattangadi-Gluth JA (2017) Types and distribution of payments from industry to physicians in 2015. JAMA 317(17):1774–1784
    • View reference on publisher's website
    • View reference on PubMed
  8. Centers for Medicare & Medicaid Services (2018) About open payments data. https://openpaymentsdata.cms.gov/about. Accessed 8 Apr 2018
  9. Liu JJ, Bell CM, Matelski JJ, Detsky AS, Cram P (2017) Payments by US pharmaceutical and medical device manufacturers to US medical journal editors: retrospective observational study. BMJ (Clin Res Ed) 359:j4619
    • View reference on publisher's website
  10. Lundh A, Barbateskovic M, Hrobjartsson A, Gotzsche PC (2010) Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue—cohort study. PLoS Med 7(10):e1000354
    • View reference on publisher's website
    • View reference on PubMed
  11. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. http://www.icmje.org/. Accessed 24 May 2018
  12. Matheson A (2016) The ICMJE Recommendations and pharmaceutical marketing–strengths, weaknesses and the unsolved problem of attribution in publication ethics. BMC Med Ethics. 17:20
    • View reference on publisher's website
    • View reference on PubMed
  13. Loder E, Brizzell C, Godlee F (2015) Revisiting the commercial-academic interface in medical journals. BMJ (Clin Res Ed) 350:h2957
  14. Wang X, Chen Y, Yao L, Zhou Q, Wu Q, Estill J et al (2017) Declarations and conflicts of interest in WHO guidelines. J Clin Epidemiol. https://doi.org/10.1016/j.jclinepi.2017.12.021
    • View reference on publisher's website
    • View reference on PubMed
  15. Andreatos N, Zacharioudakis IM, Zervou FN, Muhammed M, Mylonakis E (2017) Discrepancy between financial disclosures of authors of clinical practice guidelines and reports by industry. Med (Baltim) 96(2):e5711
    • View reference on publisher's website
  16. Morciano C, Basevi V, Faralli C, Hilton Boon M, Tonon S, Taruscio D (2016) Policies on conflicts of interest in health care guideline development: a cross-sectional analysis. PLoS One 11(11):e0166485
    • View reference on publisher's website
    • View reference on PubMed
  17. Edmond M, Eickhoff TC (2008) Who is steering the ship? External influences on infection control programs. Clin Infect Dis 46(11):1746–1750
    • View reference on publisher's website
    • View reference on PubMed
  18. Campbell EG, Weissman JS, Ehringhaus S, Rao SR, Moy B, Feibelmann S et al (2007) Institutional academic industry relationships. JAMA 298(15):1779–1786
    • View reference on publisher's website
    • View reference on PubMed
  19. Angell M (2000) Is academic medicine for sale? N Engl J Med 342(20):1516–1518
    • View reference on publisher's website
    • View reference on PubMed
  20. Resnik DB (2015) Institutional conflicts of interest in academic research. Sci Eng Ethics. https://doi.org/10.1007/s11948-015-9702-9
    • View reference on publisher's website
    • View reference on PubMed
  21. Resnik DB, Ariansen JL, Jamal J, Kissling GE (2016) Institutional conflict of interest policies at US. Academic research institutions. Acad Med 91(2):242–246
    • View reference on publisher's website
    • View reference on PubMed
  22. Scheffer P, Guy-Coichard C, Outh-Gauer D, Calet-Froissart Z, Boursier M, Mintzes B et al (2017) Conflict of interest policies at French medical schools: starting from the bottom. PLoS One 12(1):e0168258
    • View reference on publisher's website
    • View reference on PubMed
  23. Grande D, Frosch DL, Perkins AW, Kahn BE (2009) Effect of exposure to small pharmaceutical promotional items on treatment preferences. Arch Intern Med 169(9):887–893
    • View reference on publisher's website
    • View reference on PubMed
  24. Larkin I, Ang D, Steinhart J, Chao M, Patterson M, Sah S et al (2017) Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA 317(17):1785–1795
    • View reference on publisher's website
    • View reference on PubMed
  25. Epstein AJ, Busch SH, Busch AB, Asch DA, Barry CL (2013) Does exposure to conflict of interest policies in psychiatry residency affect antidepressant prescribing? Med Care 51(2):199–203
    • View reference on publisher's website
    • View reference on PubMed
  26. King M, Essick C, Bearman P, Ross JS (2013) Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis. BMJ (Clin Res Ed) 346:f264
  27. Beyhun NE, Kolayli CC, Can G, Topbas M (2016) Turkish final year medical students’ exposure to and attitudes concerning drug company interactions: a perspective from a minimally regulated environment for medical students. PLoS One 11(12):e0168094
    • View reference on publisher's website
    • View reference on PubMed
  28. Filippiadou M, Kouvelas D, Garyfallos G, Tsakiridis I, Tzachanis D, Spachos D et al (2017) Exposure to the drug company marketing in Greece: interactions and attitudes in a non-regulated environment for medical students. Ann Med Surg 19:23–28
    • View reference on publisher's website
  29. Jahnke K, Kremer MS, Schmidt CO, Kochen MM, Chenot JF (2014) German medical students’ exposure and attitudes toward pharmaceutical promotion: a cross-sectional survey. GMS Zeitschrift fur Medizinische Ausbildung 31(3):Doc32
    • View reference on PubMed
  30. Austad KE, Avorn J, Kesselheim AS (2011) Medical students’ exposure to and attitudes about the pharmaceutical industry: a systematic review. PLoS Med 8(5):e1001037
    • View reference on publisher's website
    • View reference on PubMed
  31. Bekelman JE, Li Y, Gross CP (2003) Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 289(4):454–465
    • View reference on publisher's website
    • View reference on PubMed
  32. Saito H, Gill CJ (2014) How frequently do the results from completed US clinical trials enter the public domain?–A statistical analysis of the ClinicalTrials.gov database. PLoS One 9(7):e101826
    • View reference on publisher's website
    • View reference on PubMed
  33. Jones CW, Handler L, Crowell KE, Keil LG, Weaver MA, Platts-Mills TF (2013) Non-publication of large randomized clinical trials: cross sectional analysis. BMJ (Clin Res Ed) 347:f6104
  34. Bassler D, Mueller KF, Briel M, Kleijnen J, Marusic A, Wager E et al (2016) Bias in dissemination of clinical research findings: structured OPEN framework of what, who and why, based on literature review and expert consensus. BMJ Open 6(1):e010024
    • View reference on publisher's website
    • View reference on PubMed
  35. Evoniuk G, Mansi B, DeCastro B, Sykes J (2017) Impact of study outcome on submission and acceptance metrics for peer reviewed medical journals: 6 year retrospective review of all completed GlaxoSmithKline human drug research studies. BMJ (Clin Res Ed) 357:j1726
    • View reference on publisher's website
  36. Spiegel R, Opic P, Semmlack S, Tschudin-Sutter S, Sutter R (2017) Tackling submission and publication bias. BMJ (Clin Res Ed) 358:j3436
    • View reference on publisher's website
  37. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:MR000033
    • View reference on PubMed
  38. Boutron I, Dutton S, Ravaud P, Altman DG (2010) Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 303(20):2058–2064
    • View reference on publisher's website
    • View reference on PubMed
  39. Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaud P (2014) Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. J Clin Oncol 32(36):4120–4126
    • View reference on publisher's website
    • View reference on PubMed
  40. Yavchitz A, Boutron I, Bafeta A, Marroun I, Charles P, Mantz J et al (2012) Misrepresentation of randomized controlled trials in press releases and news coverage: a cohort study. PLoS Med 9(9):e1001308
    • View reference on publisher's website
    • View reference on PubMed
  41. Kaestner V, Brown A, Tao D, Prasad V (2017) Conflicts of interest in twitter. Lancet Haematol 4(9):e408–e409
    • View reference on publisher's website
    • View reference on PubMed
  42. Tao DL, Boothby A, McLouth J, Prasad V (2017) Financial conflicts of interest among hematologist-oncologists on twitter. JAMA Intern Med 177(3):425–427
    • View reference on publisher's website
    • View reference on PubMed
  43. Huttner A, Kaiser L (2017) Fair reporting of study results. Clin Microbiol Infect 23(6):345–346
    • View reference on publisher's website
    • View reference on PubMed
  44. World Medical A (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191–2194
    • View reference on publisher's website
  45. Jacmon H (2018) Disclosure is inadequate as a solution to managing conflicts of interest in human research. J Bioeth Inq 15(1):71–80
    • View reference on publisher's website
    • View reference on PubMed
  46. Hurst SA, Mauron A (2008) A question of method. The ethics of managing conflicts of interest. EMBO Rep 9(2):119–123
    • View reference on publisher's website
    • View reference on PubMed
  47. World Health Organization (2014) WHO handbook for guideline development, 2nd edn. World Health Organization, Geneva
  48. World Health Organization International Clinical Trials Registry Platform (ICTRP). Joint statement on public disclosure of results from clinical trials. http://www.who.int/ictrp/results/ICTRP_JointStatement_2017.pdf?ua=1. Accessed 8 April 2018
  49. Nelson D, McNeill R. Money from infection-control industry muddies research into beating back superbugs. Reuters investigates [internet]. http://www.reuters.com/investigates/special-report/usa-superbugs-research/. Accessed 5 April 2018
  50. Vernon MO, Hayden MK, Trick WE, Hayes RA, Blom DW, Weinstein RA et al (2006) Chlorhexidine gluconate to cleanse patients in a medical intensive care unit: the effectiveness of source control to reduce the bioburden of vancomycin-resistant enterococci. Arch Intern Med 166(3):306–312
    • View reference on publisher's website
    • View reference on PubMed
  51. Bleasdale SC, Trick WE, Gonzalez IM, Lyles RD, Hayden MK, Weinstein RA (2007) Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 167(19):2073–2079
    • View reference on publisher's website
    • View reference on PubMed
  52. Climo MW, Yokoe DS, Warren DK, Perl TM, Bolon M, Herwaldt LA et al (2013) Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 368(6):533–542
    • View reference on publisher's website
    • View reference on PubMed
  53. Munoz-Price LS, Hota B, Stemer A, Weinstein RA (2009) Prevention of bloodstream infections by use of daily chlorhexidine baths for patients at a long-term acute care hospital. Infect Control Hosp Epidemiol 30(11):1031–1035
    • View reference on publisher's website
    • View reference on PubMed
  54. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK (2009) Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 30(10):959–963
    • View reference on publisher's website
    • View reference on PubMed
  55. Popovich KJ, Hota B, Hayes R, Weinstein RA, Hayden MK (2010) Daily skin cleansing with chlorhexidine did not reduce the rate of central-line associated bloodstream infection in a surgical intensive care unit. Intensive Care Med 36(5):854–858
  56. Noto MJ, Domenico HJ, Byrne DW, Talbot T, Rice TW, Bernard GR et al (2015) Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. JAMA 313(4):369–378
    • View reference on publisher's website
    • View reference on PubMed
  57. Afonso E, Blot K, Blot S (2016) Prevention of hospital-acquired bloodstream infections through chlorhexidine gluconate-impregnated washcloth bathing in intensive care units: a systematic review and meta-analysis of randomised crossover trials. Euro Surveill 21(46):30400
    • View reference on publisher's website
    • View reference on PubMed
  58. Frost SA, Alogso MC, Metcalfe L, Lynch JM, Hunt L, Sanghavi R et al (2016) Chlorhexidine bathing and health care-associated infections among adult intensive care patients: a systematic review and meta-analysis. Crit Care 20(1):379 (London, England)
    • View reference on publisher's website
    • View reference on PubMed
  59. Shirahatti RG, Joshi RM, Vishwanath YK, Shinkre N, Rao S, Sankpal JS et al (1993) Effect of pre-operative skin preparation on post-operative wound infection. J Postgrad Med 39(3):134–136
    • View reference on PubMed
  60. Weiner LM, Webb AK, Walters MS, Dudeck MA, Kallen AJ (2016) Policies for controlling multidrug-resistant organisms in US healthcare facilities reporting to the national healthcare safety network, 2014. Infect Control Hosp Epidemiol 37(9):1105–1108
    • View reference on publisher's website
    • View reference on PubMed
  61. Food and Drug Administration. Warning letter. https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2017/ucm568120.htm. Accessed 14 May 2018
  62. Harbarth S, Tuan Soh S, Horner C, Wilcox MH (2014) Is reduced susceptibility to disinfectants and antiseptics a risk in healthcare settings? A point/counterpoint review. J Hosp Infect 87(4):194–202
    • View reference on publisher's website
    • View reference on PubMed
  63. Kampf G (2016) Acquired resistance to chlorhexidine—is it time to establish an ‘antiseptic stewardship’ initiative? J Hosp Infect 94(3):213–227
    • View reference on publisher's website
    • View reference on PubMed
  64. Beattie AH, Prach AT, Baxter JP, Pennington CR (2000) A randomised controlled trial evaluating the use of enteral nutritional supplements postoperatively in malnourished surgical patients. Gut 46(6):813–818
    • View reference on publisher's website
    • View reference on PubMed
  65. Wu AW, Kavanagh KT, Pronovost PJ, Bates DW (2014) Conflict of interest, Dr Charles Denham and the journal of patient safety. J Patient Saf 10(4):181–185
    • View reference on publisher's website
    • View reference on PubMed
  66. Department of Justice. CareFusion to pay the government $40.1 Million to resolve allegations that include more than $11 million in kickbacks to one doctor. https://www.justice.gov/opa/pr/carefusion-pay-government-401-million-resolve-allegations-include-more-11-million-kickbacks. Accessed 14 May 2018
  67. Department of Justice. United States settles false claims act allegations against patient safety consultant and his companies. https://www.justice.gov/opa/pr/united-states-settles-false-claims-act-allegations-against-patient-safety-consultant-and-his. Accessed 14 May 2018
  68. Weber DJ, Otter JA, Rutala WA (2017) Can copper-coated surfaces prevent healthcare-associated infections? Infect Control Hosp Epidemiol 38(7):772–776
    • View reference on publisher's website
    • View reference on PubMed
  69. Salgado CD, Sepkowitz KA, John JF, Cantey JR, Attaway HH, Freeman KD et al (2013) Copper surfaces reduce the rate of healthcare-acquired infections in the intensive care unit. Infect Control Hosp Epidemiol 34(5):479–486
    • View reference on publisher's website
    • View reference on PubMed
  70. Harbarth S, Maiwald M, Dancer SJ (2013) The environment and healthcare-acquired infections: why accurate reporting and evaluation of biological plausibility are important. Infect Control Hosp Epidemiol 34(9):996–997
    • View reference on publisher's website
    • View reference on PubMed
  71. Souli M, Antoniadou A, Katsarolis I, Mavrou I, Paramythiotou E, Papadomichelakis E et al (2017) Reduction of environmental contamination with multidrug-resistant bacteria by copper-alloy coating of surfaces in a highly endemic setting. Infect Control Hosp Epidemiol 38(7):765–771
    • View reference on publisher's website
    • View reference on PubMed
  72. von Dessauer B, Navarrete MS, Benadof D, Benavente C, Schmidt MG (2016) Potential effectiveness of copper surfaces in reducing health care-associated infection rates in a pediatric intensive and intermediate care unit: a nonrandomized controlled trial. Am J Infect Control 44(8):e133–e139
    • View reference on publisher's website
  73. Muller MP, MacDougall C, Lim M, Ontario Agency for Health P, Promotion Public Health O, Provincial Infectious Diseases Advisory Committee on Infection P et al (2016) Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review. J Hosp Infect 92(1):7–13
    • View reference on publisher's website
    • View reference on PubMed
  74. Schmidt MG, Salgado CD, Freeman KD, John JF, Cantey JR, Sharpe PA et al (2018) Antimicrobial surfaces to prevent healthcare-associated infections: a systematic review—a different view. J Hosp Infect 99(3):309–311
    • View reference on publisher's website
    • View reference on PubMed
  75. Butler JP (2018) Effect of copper-impregnated composite bed linens and patient gowns on healthcare-associated infection rates in six hospitals. J Hosp Infect. https://doi.org/10.1016/j.jhin.2018.05.013
    • View reference on publisher's website
    • View reference on PubMed
  76. Abbas M, Pires D, Harbarth S, de Kraker MEA (2018) Infection prevention: is copper the new gold? J Hosp Infect. https://doi.org/10.1016/j.jhin.2018.06.012
    • View reference on publisher's website
    • View reference on PubMed
  77. Rosenthal VD, Maki DG, Graves N (2008) The International Nosocomial Infection Control Consortium (INICC): goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 36(9):e1–e12
    • View reference on publisher's website
    • View reference on PubMed
  78. Rosenthal VD (2016) International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. Am J Infect Control 44(6):e81–e90
    • View reference on publisher's website
    • View reference on PubMed
  79. Rosenthal VD, Guzman S, Crnich C (2004) Device-associated nosocomial infection rates in intensive care units of Argentina. Infect Control Hosp Epidemiol 25(3):251–255
    • View reference on publisher's website
    • View reference on PubMed
  80. Rangel-Frausto MS, Higuera-Ramirez F, Martinez-Soto J, Rosenthal VD (2010) Should we use closed or open infusion containers for prevention of bloodstream infections? Ann Clin Microbiol Antimicrob 9:6
    • View reference on publisher's website
    • View reference on PubMed
  81. Vilins M, Blecher S, Silva MA, Rosenthal VD, Barker K, Salomao R (2009) Rate and time to develop first central line-associated bloodstream infections when comparing open and closed infusion containers in a Brazilian Hospital. Braz J Infect Dis 13(5):335–340
    • View reference on publisher's website
    • View reference on PubMed
  82. Franzetti F, Borghi B, Raimondi F, Rosenthal VD (2009) Impact on rates and time to first central vascular-associated bloodstream infection when switching from open to closed intravenous infusion containers in a hospital setting. Epidemiol Infect 137(7):1041–1048
    • View reference on publisher's website
    • View reference on PubMed
  83. Maki DG, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS (2011) Impact of switching from an open to a closed infusion system on rates of central line-associated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. Infect Control Hosp Epidemiol 32(1):50–58
    • View reference on publisher's website
    • View reference on PubMed
  84. Graves N, Barnett AG, Rosenthal VD (2011) Open versus closed IV infusion systems: a state based model to predict risk of catheter associated blood stream infections. BMJ Open 1(2):e000188
    • View reference on publisher's website
    • View reference on PubMed
  85. Mainous MR, Deitch EA (1994) Nutrition and infection. Surg Clin North Am 74(3):659–676
    • View reference on PubMed
  86. Mazaki T, Ishii Y, Murai I (2015) Immunoenhancing enteral and parenteral nutrition for gastrointestinal surgery: a multiple-treatments meta-analysis. Ann Surg 261(4):662–669
    • View reference on publisher's website
    • View reference on PubMed
  87. Haustein T, Gastmeier P, Holmes A, Lucet JC, Shannon RP, Pittet D et al (2011) Use of benchmarking and public reporting for infection control in four high-income countries. Lancet Infect Dis 11(6):471–481
    • View reference on publisher's website
    • View reference on PubMed
  88. Masnick M, Morgan DJ, Sorkin JD, Kim E, Brown JP, Rheingans P et al (2016) Lack of patient understanding of hospital-acquired infection data published on the centers for medicare and medicaid services hospital compare website. Infect Control Hosp Epidemiol 37(2):182–187
    • View reference on publisher's website
    • View reference on PubMed
  89. Mitchell BG, Shaban RZ, MacBeth D, Wood CJ, Russo PL (2017) The burden of healthcare-associated infection in Australian hospitals: a systematic review of the literature. Infect Dis Health 22(3):117–128
    • View reference on publisher's website
  90. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L et al (2011) Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet 377(9761):228–241 (London, England)
    • View reference on publisher's website
  91. Lee GM, Kleinman K, Soumerai SB, Tse A, Cole D, Fridkin SK et al (2012) Effect of nonpayment for preventable infections in US hospitals. N Engl J Med 367(15):1428–1437
    • View reference on publisher's website
    • View reference on PubMed
  92. Ashley EA, Recht J, Chua A, Dance D, Dhorda M, Thomas NV et al (2018) An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. J Antimicrob Chemother 73(7):1737–1749
    • View reference on publisher's website
  93. Monnet DL (2000) Toward multinational antimicrobial resistance surveillance systems in Europe. Int J Antimicrob Agents 15(2):91–101
    • View reference on publisher's website
    • View reference on PubMed
  94. Tacconelli E, Sifakis F, Harbarth S, Schrijver R, van Mourik M, Voss A et al (2018) Surveillance for control of antimicrobial resistance. Lancet Infect Dis 18(3):e99–e106
    • View reference on publisher's website
    • View reference on PubMed
  95. World Health Organization (2018) Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016–2017. World Health Organization, Geneva
  96. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R et al (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 10(9):597–602
    • View reference on publisher's website
    • View reference on PubMed
  97. European Centre for Disease Prevention and Control (2011) Updated risk assessment on the spread of NDM and its variants within Europe. ECDC, Stockholm
  98. Pesesky MW, Hussain T, Wallace M, Wang B, Andleeb S, Burnham CA et al (2015) KPC and NDM-1 genes in related enterobacteriaceae strains and plasmids from Pakistan and the United States. Emerg Infect Dis 21(6):1034–1037
    • View reference on publisher's website
    • View reference on PubMed
  99. Chen D, Gong L, Walsh TR, Lan R, Wang T, Zhang J et al (2016) Infection by and dissemination of NDM-5-producing Escherichia coli in China. J Antimicrob Chemother 71(2):563–565
    • View reference on publisher's website
    • View reference on PubMed
  100. Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K et al (2009) Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53(12):5046–5054
    • View reference on publisher's website
    • View reference on PubMed
  101. Walsh TR, Weeks J, Livermore DM, Toleman MA (2011) Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 11(5):355–362
    • View reference on publisher's website
    • View reference on PubMed
  102. Mohapatra PR (2013) Metallo-beta-lactamase 1—why blame New Delhi & India? Indian J Med Res 137(1):213–215
    • View reference on PubMed
  103. BBC News. ‘New Delhi’ superbug named unfairly, says Lancet editor. http://www.bbc.com/news/world-south-asia-12172633. Accessed 08 May 2018
  104. Derde LP, Dautzenberg MJ, Bonten MJ (2012) Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Med 38(6):931–939
  105. Bretagnol F, Panis Y, Rullier E, Rouanet P, Berdah S, Dousset B et al (2010) Rectal cancer surgery with or without bowel preparation: the French GRECCAR III multicenter single-blinded randomized trial. Ann Surg 252(5):863–868
    • View reference on publisher's website
    • View reference on PubMed
  106. Steen RG, Casadevall A, Fang FC (2013) Why has the number of scientific retractions increased? PLoS One 8(7):e68397
    • View reference on publisher's website
    • View reference on PubMed
  107. Saver RS (2012) Is it really all about the money? Reconsidering non-financial interests in medical research. J Law Med Eth 40(3):467–481
    • View reference on publisher's website
  108. Wiersma M, Kerridge I, Lipworth W, Rodwin M (2018) Should we try to manage non-financial interests? BMJ (Clin Res Ed) 361:k1240
    • View reference on publisher's website
  109. Casadevall A, Fang FC (2014) Causes for the persistence of impact factor mania. MBio. https://doi.org/10.1128/mBio.00064-14
    • View reference on publisher's website
    • View reference on PubMed
  110. Casadevall A, Bertuzzi S, Buchmeier MJ, Davis RJ, Drake H, Fang FC et al (2016) ASM journals eliminate impact factor information from journal websites. Clin Microbiol Rev. https://doi.org/10.1128/CMR.00070-16
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement